Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Autologous stem cell transplants in lymphomas

E A Vandenberghe1, A H Goldstone

  • 1University College London Hospitals, UK.

Annals of Medicine
|April 1, 1996
PubMed
Summary

High-dose chemotherapy with stem cell rescue offers a safe and effective treatment for relapsed or poor-prognosis lymphomas. This approach significantly improves outcomes for patients with Hodgkin

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Durable benefit of rituximab maintenance post-autograft in patients with relapsed follicular lymphoma: 12-year follow-up of the EBMT lymphoma working party Lym1 trial.

Bone marrow transplantation·2021
Same author

The evolving role of chemotherapy and hematopoietic cell transplants in Ph-positive acute lymphoblastic leukemia in adults.

Bone marrow transplantation·2017
Same author

Autologous Bone-Marrow Transplantation in Acute Lymphoblastic Leukaemia: 1980-89.

Leukemia & lymphoma·2016
Same author

Systemic Irradiation Therapy of Myelomatosis-The Therapeutic Implications of Technique.

Leukemia & lymphoma·2016
Same author

Scabies Infestation following Autologous Bone Marrow Transplantation.

Leukemia & lymphoma·2016
Same author

Recombinant Alpha 2A Interferon-An Effective Maintenance Agent in Essential Thrombocythaemia.

Leukemia & lymphoma·2016

Area of Science:

  • Hematology
  • Oncology
  • Cancer Research

Background:

  • Hodgkin's disease and non-Hodgkin's lymphomas are treatable with first-line therapies.
  • Relapse in lymphoma is not always fatal but often requires intensive, myelotoxic treatments.
  • High-dose chemotherapy followed by hematopoietic stem cell transplantation has emerged as a viable option for relapsed disease.

Purpose of the Study:

  • To review the clinical indications for high-dose therapy in lymphoma management.
  • To compare the advantages of autologous bone marrow versus peripheral stem cell transplants.
  • To discuss current practices in peripheral stem cell mobilization and harvesting.

Main Methods:

  • Review of clinical indications for high-dose therapy in lymphoma.
  • Comparison of autologous bone marrow and peripheral stem cell transplantation.
  • Discussion of peripheral stem cell mobilization and harvesting techniques.

Main Results:

  • High-dose chemotherapy with hematopoietic stem cell rescue is relatively safe, with mortality rates as low as 2% in some centers.
  • This approach makes intensive chemotherapy feasible for patients with relapsed or poor-prognosis lymphoma.
  • Autologous stem cell transplantation has significantly improved the management of relapsed lymphoma.

Conclusions:

  • High-dose therapy with autologous stem cell rescue is a safe and effective strategy for managing relapsed and poor-prognosis lymphomas.
  • The choice between autologous bone marrow and peripheral stem cell transplantation depends on specific clinical factors.
  • Advances in stem cell mobilization and harvesting have enhanced the safety and efficacy of this treatment modality.

Related Experiment Videos